Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media.

[1]  R. Campbell,et al.  Effect of monoclonal antibody drug therapy on mucosal biomarkers in airway disease: A systematic review , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[2]  A. Nanzer,et al.  Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma. , 2020, Chest.

[3]  G. Ortega,et al.  Combination Biologic Therapy for Severe Persistent Asthma. , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[4]  S. Szefler,et al.  Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic? , 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[5]  D. Hira,et al.  Effect of nasally exhaling budesonide/formoterol dry powder inhaled at "fast" inspiratory flow on eosinophilic chronic rhinosinusitis
. , 2018, International journal of clinical pharmacology and therapeutics.

[6]  T. Morikawa,et al.  Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study , 2015, Allergy.

[7]  A. Zwinderman,et al.  Severe adult-onset asthma: A distinct phenotype. , 2013, The Journal of allergy and clinical immunology.

[8]  T. Nakagawa,et al.  Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. , 2011, Auris, nasus, larynx.

[9]  W. Busse,et al.  Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. , 2010, The Journal of allergy and clinical immunology.